Crisaborole — Active Pharmaceutical Ingredient

Crisaborole is an active pharmaceutical ingredient found in 2 FDA-approved drug products. Forms: OINTMENT. Routes: TOPICAL.

This content is for informational purposes only. Always consult a healthcare professional.

Crisaborole (2 brand names, 1 dosage form, 1 route)

Available dosage forms: OINTMENT.

Routes of administration: TOPICAL.

Brand Names

  • CRISABOROLE
  • EUCRISA

Indications and Usage

EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

Dosage and Administration

Apply a thin layer of EUCRISA twice daily to affected areas. Once clinical effect is achieved, consider reducing application to once daily [see Clinical Studies (14) ]. EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use.

Contraindications

EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. [see Warnings and Precautions (5.1)]

Mechanism of Action

Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.